Turning on Tregs

Although expanding Tregs to treat autoimmune diseases offers a safer alternative to general immunosuppression, the challenge has been to target only those cells, and avoid stimulating T cells that will exacerbate disease. By homing in a form of the IL-2 receptor only on Tregs, Delinia Inc. has carved a way to potentiate the suppressive pathway alone.

Delinia was launched earlier this year to develop a Treg-targeting biologic based on IL-2 receptor technology created by its CSO Jeffrey Greve, and in June raised a $35 million series A round from Atlas Venture and Sofinnova Partners...